Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

BACKGROUND: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease, including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Circulation
Main Authors: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei, Rosenthal, Norm, Jardine, Meg J., Bakris, George, Perkovic, Vlado
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2018
Teme:
Original Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://ncbi.nlm.nih.gov/pubmed/29941478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki